<DOC>
	<DOCNO>NCT02154776</DOCNO>
	<brief_summary>This multi-center , open-label , non-randomized , phase I study</brief_summary>
	<brief_title>Dose Escalation Study LEE011 Combination With Buparlisib Letrozole HR+ , HER2-negative Post-menopausal Women With Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Women advance ( recurrent metastatic ) breast cancer receive prior therapy advance disease . 2 . Patient postmenopausal . 3 . Patient may receive â‰¤ 2 line chemotherapy metastatic recurrent breast cancer doseescalation phase . 4 . Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer local laboratory . 5 . Patient HER2negative breast cancer define negative situ hybridization test IHC status 0 , 1+ 2+ . If IHC 2+ , negative situ hybridization ( FISH , CISH , SISH ) test require local laboratory test . 6 . Patient must either : Measurable disease , i.e. , least one measurable lesion per RECIST 1.1 criterion least one predominantly lytic bone lesion 1 . Patient receive CDK4/6 PI3K inhibitor . 2 . Patient active cardiac disease history cardiac dysfunction include follow : History angina pectoris , symptomatic pericarditis , myocardial infarction within 12 month prior study entry History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Patient Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) History cardiac arrhythmia , e.g. , ventricular , supraventricular , nodal arrhythmia , conduction abnormality previous 12 month . On screening , follow cardiac parameter : bradycardia ( heart rate &lt; 50 rest ) , tachycardia ( heart rate &gt; 90 rest ) , PR interval &gt; 220 msec , QRS interval &gt; 109 msec , QTcF &gt; 450 msec . Systolic blood pressure &gt; 160 &lt; 90 mmHg 3 . Patient currently receive follow medication : That know strong inducer inhibitor CYP3A4 . That know risk prolong QT interval induce Torsades de Pointes . That narrow therapeutic window predominantly metabolize CYP3A4 . 4 . Certain score anxiety depression mood questionnaire</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>LEE011 ,</keyword>
	<keyword>buparlisib ,</keyword>
	<keyword>letrozole ,</keyword>
	<keyword>HR + ,</keyword>
	<keyword>HER2 - negative ,</keyword>
	<keyword>post-menopausal ,</keyword>
	<keyword>breast cancer ,</keyword>
	<keyword>CDK 4/6 ,</keyword>
	<keyword>PI3K ,</keyword>
	<keyword>MTD</keyword>
</DOC>